市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | GH Research PLC | 混合的 | 看涨 |
AIStockmoo 评分
-0.7
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | -0.5 |
| 相对估值 | NA |
| 财务健康 | NA |
| AI Insight | NA |
| 平均 | -0.67 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 33.88% |
| 机构持股比例 | 68.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Lynx1 Capital Management Lp | 30 Jun 2026 | 13,263,288 |
| Bvf Inc/Il | 30 Jun 2026 | 8,650,158 |
| Ra Capital Management, L.P. | 30 Jun 2026 | 7,636,813 |
| Rtw Investments, Lp | 30 Jun 2026 | 5,933,815 |
| Deep Track Capital, Lp | 30 Jun 2026 | 3,333,334 |
| Avoro Capital Advisors Llc | 30 Jun 2026 | 1,800,000 |
| Foresite Capital Management Vi Llc | 30 Jun 2026 | 940,493 |
| Jefferies Financial Group Inc. | 30 Jun 2026 | 712,300 |
| Braidwell Lp | 30 Jun 2026 | 207,240 |
| Boothbay Fund Management, Llc | 30 Jun 2026 | 202,103 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合